Neurooncology Tuebingen
@neurooncotue.bsky.social
Interdiciplinary neurooncologcial activities and research at the Tuebinger university hospital 🧠 @hih-tuebingen.bsky.social 🎓 @unituebingen.bsky.social 🧠 Website: https://www.hih-tuebingen.de/forschung/neuroonkologie
We are very happy to present you our work, recently accepted in Neurooncology! @ghtabatabai.bsky.social @hih-tuebingen.bsky.social academic.oup.com/neuro-oncolo...
Molecular modulators of CDK4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening
AbstractBackground. Glioblastoma harbors frequent alterations in the retinoblastoma (RB1) pathway, providing a genetic rationale for therapeutic targeting
academic.oup.com
Now Daniel Merk presents his work at the DGN in Berlin. @dgn-ev.bsky.social @ghtabatabai.bsky.social @hih-tuebingen.bsky.social
Very happy to had the opportunity to present our data at the DGN in Berlin. @ghtabatabai.bsky.social @hih-tuebingen.bsky.social @dgn-ev.bsky.social
Neurooncology Tuebingen@neurooncotue.bsky.social · 9mo agoWe are very happy to present our data at the DGN in Berlin! @ghtabatabai.bsky.social @hannes-becker1996.bsky.social @dgn-ev.bsky.social
We are very happy to present our data at the DGN in Berlin! @ghtabatabai.bsky.social @hannes-becker1996.bsky.social @dgn-ev.bsky.social
We had a wonderful #eano2025 in Prague, with multiple talks and poster presentations and fruitful discussions! Looking forward to Rome! @eanoassociation.bsky.social @ghtabatabai.bsky.social @hannes-becker1996.bsky.social @nihalolcaydogan.bsky.social @hih-tuebingen.bsky.social
Now Surender Surender on stage, presenting our data on CDK4/6 inhibition in experimental glioma! @eanoassociation.bsky.social @ghtabatabai.bsky.social @hih-tuebingen.bsky.social
Great talk by @ghtabatabai.bsky.social about time management in academia @eanoassociation.bsky.social
Great poster session with nice discussions about our current work! @eanoassociation.bsky.social @ghtabatabai.bsky.social @hannes-becker1996.bsky.social @nihalolcaydogan.bsky.social @hih-tuebingen.bsky.social
Nice opportunity to present our data on regorafenib in combination with navitoclax at @eanoassociation.bsky.social @hannes-becker1996.bsky.social @ghtabatabai.bsky.social
Ghazaleh Tabatabai@ghtabatabai.bsky.social · 10mo agoAnd now it‘s Hannes Becker on stage, presenting our data at EANO2025 👍🏼🙌 @neurooncotue.bsky.social
Just happening. Max Niyazi on stage at EANO 2025 👍🏼💡
Great comprehensive talk by @ghtabatabai.bsky.social to give insights into CRISPR screen. More to come! @eanoassociation.bsky.social
🧠 Just published in Neuro-Oncology: A comprehensive consensus review by @neuroonc.bsky.social and EANO on current management and future directions in adult #Glioblastoma care. Explore key recommendations and research priorities. 🔗 academic.oup.com/neuro-oncolo... #NeuroOncology
🚨 At #EANO2025, we already expect more than 1,200 participants! Don’t miss out on this fantastic experience to meet experts in the field of #NeuroOncology from all over the world. Registration is still open eano.eu/eano2025/ We can’t wait to see you in #Prague!
🧠 Recently published in Neuro-Oncology: EANS–EANO Guidelines on the Extent of Resection in Gliomas. We’re proud to share the outcome of collaborative effort by the joint task force of EANS and EANO, providing evidence-based recommendations for clinical practice. 🔗 academic.oup.com/neuro-oncolo...
Innovative trial design, thank you for the opportunity for being part of it!
EANO@eanoassociation.bsky.social · 11mo ago🧠 The phase 1/2 N2M2 umbrella trial lead by former EANO president @wickwolfgang.bsky.social has just been published in Nature Medicine 🔗 www.nature.com/articles/s41... #NeuroOncology #EANOessentials #BrainTumors #CancerResearch
Extremely happy that we could have contributed!
Michael Platten, MD@michael-platten.bsky.social · last yr.Excited to announce that we have completed accrual of the INTERCEPT-H3 trial (NCT04808245). This phase 1 first-in-human trial explores safety and immunogenicity of a long peptide vaccine targeting the clonal driver mutation H3K27M in adult patients with newly diagnosed diffuse midline gliomas 1/
Almost 25 year old T-shirt, reminds me of great experience at MGH/HMS 2000/2001, @harvard.edu - hard to see this institution under pressure now, and impressed by the integrity and resilience of Harvard leadership (more on LinkedIn) 🙌 #Harvard #AcademicFreedom #ScienceForDemocracy #ScienceMatters
Tübingen 12 Feb 2025 Geschwister Scholl Platz Democracy needs facts Science needs Democracy. #aufstehenfuerdemokratie
We are more than happy that our publication "The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy" is accepted by Neurooncology Advances. academic.oup.com/noa/advance-... Check it out ;) @unituebingen.bsky.social @hih-tuebingen.bsky.social
The Immunopeptidomic Landscape of Ependymomas Provides Actionable Antigens for T Cell-Based Immunotherapy
AbstractBackground. Ependymoma are primary tumors of the nervous system. Due to their growth pattern, many ependymomas can be managed with neurosurgical re
academic.oup.com
👍 Herzlich Willkommen auf dem Bluesky-Account der #unituebingen. Wir posten ab sofort hier und auf unseren anderen Kanälen, z.B. Instagram, Facebook, LinkedIn, Mastodon. Unsere Aktivitäten auf X haben wir beendet.
Happy to see this finally out after a long team effort! 🎉🎉🎉 @hih-tuebingen.bsky.social @ghtabatabai.bsky.social
Ghazaleh Tabatabai@ghtabatabai.bsky.social · 2y agoNEW publication from our Lab 🥳💫🥳Genome-wide CRISPR-Cas9 screens identify identify BCL family members as modulators of response to regorafenib in experimental glioma. @neurooncotue.bsky.social pubmed.ncbi.nlm.nih.gov/39756423/
Merry Christmas and very best wishes für 2025! @hih-tuebingen.bsky.social @unituebingen.bsky.social @neurooncotue.bsky.social
New insights into #meningiomas, with The Brain Tumour Charity’s funding and led by @gelarehzadeh.bsky.social, has been included in their #Research Highlights of 2024. Read more about it here: www.thebraintumourcharity.org/news/researc...
Two flagship chair professorships for neurodgenerative diseases in Tübingen, Germany. Both affiliated with our university @hih-tuebingen.bsky.social and the German Center for Neurodegenerative diseases @dzne.science. Apply and join us! www.nature.com/naturecareer... www.nature.com/naturecareer...
Nature Careers | Science jobs | Choose from 1,225 live vacancies
Search for your next job from 1,225 live vacancies, or upload your CV now and let recruiters find you
nature.com
📢The Faculty of Medicine at the University of Tübingen invites applications for a position at the Hertie Center for Neurology for an Endowed #Professorship (W3) in #Neurology with a Focus on #Neurodegenerative #Diseases, available by 1 October 2026, potentially earlier Full PDF: tinyurl.com/y6bfky83
@ghtabatabai is a neurologist and a physician scientist at the University of Tübingen and the Managing Director Neurology at the University Hospital Tübingen. Her research includes target discovery & validation, molecular mechanisms of treatment resistance, & novel delivery routes to brain tumors.
Just happening in Tübingen: Great talk by Prof Ulrich Dirnagl on Research Integrity 🙌💡👍🏼 @hih-tuebingen.bsky.social
